BR112017004000A2 - formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida - Google Patents

formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida

Info

Publication number
BR112017004000A2
BR112017004000A2 BR112017004000A BR112017004000A BR112017004000A2 BR 112017004000 A2 BR112017004000 A2 BR 112017004000A2 BR 112017004000 A BR112017004000 A BR 112017004000A BR 112017004000 A BR112017004000 A BR 112017004000A BR 112017004000 A2 BR112017004000 A2 BR 112017004000A2
Authority
BR
Brazil
Prior art keywords
dimethoxyquinazolin
dimethylbenzofuran
carboxamide
crystalline forms
oxy
Prior art date
Application number
BR112017004000A
Other languages
English (en)
Other versions
BR112017004000B1 (pt
Inventor
Li Wenji
Chu Yuping
Wu Zhenping
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55458346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017004000(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of BR112017004000A2 publication Critical patent/BR112017004000A2/pt
Publication of BR112017004000B1 publication Critical patent/BR112017004000B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção refere-se a formas cristalinas do composto 6-(6,7-dimetoxiquinazolin-4-ilóxi)-n,2-dimetilbenzofuran-3-carboxamida, composições farmacêuticas e os métodos de preparação e o uso dos mesmos.
BR112017004000-0A 2014-09-10 2015-09-07 Forma i de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3- carboxamida, composição farmacêutica, uso da dita forma i ou dita composição farmacêutica e métodos de preparação da dita forma i BR112017004000B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410456350.9 2014-09-10
CN201410456350.9A CN105461702A (zh) 2014-09-10 2014-09-10 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
PCT/CN2015/089035 WO2016037550A1 (en) 2014-09-10 2015-09-07 Crystalline forms of 6- ( (6, 7-dimethoxyquinazolin-4-yl) oxy) -n,2-dimethylbenzofuran-3-carboxamide

Publications (2)

Publication Number Publication Date
BR112017004000A2 true BR112017004000A2 (pt) 2017-12-05
BR112017004000B1 BR112017004000B1 (pt) 2023-10-24

Family

ID=55458346

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004000-0A BR112017004000B1 (pt) 2014-09-10 2015-09-07 Forma i de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3- carboxamida, composição farmacêutica, uso da dita forma i ou dita composição farmacêutica e métodos de preparação da dita forma i

Country Status (31)

Country Link
US (3) US10519142B2 (pt)
EP (1) EP3191475B1 (pt)
JP (2) JP6655608B2 (pt)
KR (2) KR102221722B1 (pt)
CN (3) CN105461702A (pt)
AU (1) AU2015316010B2 (pt)
BR (1) BR112017004000B1 (pt)
CA (1) CA2958666C (pt)
CL (1) CL2017000540A1 (pt)
CY (1) CY1123892T1 (pt)
DK (1) DK3191475T3 (pt)
EA (1) EA034730B1 (pt)
ES (1) ES2819242T3 (pt)
HK (1) HK1231479A1 (pt)
HR (1) HRP20201501T1 (pt)
HU (1) HUE050580T2 (pt)
IL (1) IL250647B (pt)
LT (1) LT3191475T (pt)
MX (1) MX370791B (pt)
MY (1) MY176618A (pt)
PE (1) PE20170661A1 (pt)
PH (1) PH12017500451A1 (pt)
PL (1) PL3191475T3 (pt)
PT (1) PT3191475T (pt)
RS (1) RS60829B1 (pt)
SG (1) SG11201701544UA (pt)
SI (1) SI3191475T1 (pt)
TW (1) TWI718105B (pt)
UA (1) UA120371C2 (pt)
WO (1) WO2016037550A1 (pt)
ZA (1) ZA201701320B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105461702A (zh) * 2014-09-10 2016-04-06 和记黄埔医药（上海）有限公司 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
CN111164085B (zh) 2017-09-29 2023-04-04 杭州领业医药科技有限公司 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
CN116987069A (zh) * 2018-03-30 2023-11-03 杭州领业医药科技有限公司 呋喹替尼的共晶、其制备方法、组合物和用途
CN111184698A (zh) * 2018-11-15 2020-05-22 和记黄埔医药（上海）有限公司 呋喹替尼制剂及其应用
CN113330166B (zh) 2019-03-28 2023-05-05 住友重机械工业株式会社 挖土机
CN113200966B (zh) * 2021-04-06 2022-07-22 深圳大学 一种呋喹替尼衍生物、药物组合物和用途
GB202211142D0 (en) * 2022-07-29 2022-09-14 Macfarlan Smith Ltd Polymorphs, co-crystals and solvates of fruquintinib, processes for the preparation and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101575333B (zh) * 2008-05-09 2011-06-22 和记黄埔医药（上海）有限公司 一种喹唑啉衍生物及其医药用途
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CN105461702A (zh) * 2014-09-10 2016-04-06 和记黄埔医药（上海）有限公司 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型

Also Published As

Publication number Publication date
CN106604919A (zh) 2017-04-26
AU2015316010A8 (en) 2017-05-11
US10519142B2 (en) 2019-12-31
CA2958666C (en) 2020-10-06
JP6655608B2 (ja) 2020-02-26
EP3191475A1 (en) 2017-07-19
PL3191475T3 (pl) 2021-01-11
TWI718105B (zh) 2021-02-11
US20210276983A1 (en) 2021-09-09
US11958838B2 (en) 2024-04-16
CY1123892T1 (el) 2022-03-24
PH12017500451A1 (en) 2017-07-31
MX2017002913A (es) 2017-06-06
RS60829B1 (sr) 2020-10-30
CN106604919B (zh) 2019-11-15
MY176618A (en) 2020-08-18
PT3191475T (pt) 2020-09-04
UA120371C2 (uk) 2019-11-25
HK1231479A1 (zh) 2017-12-22
IL250647A0 (en) 2017-04-30
SG11201701544UA (en) 2017-03-30
KR102221722B1 (ko) 2021-03-03
MX370791B (es) 2020-01-08
EP3191475A4 (en) 2018-10-03
EA034730B1 (ru) 2020-03-13
HUE050580T2 (hu) 2020-12-28
DK3191475T3 (da) 2020-09-28
AU2015316010A1 (en) 2017-04-27
US20170283399A1 (en) 2017-10-05
AU2015316010B2 (en) 2018-06-14
KR20170042662A (ko) 2017-04-19
PE20170661A1 (es) 2017-05-18
EA201790275A1 (ru) 2017-10-31
CN111018846B (zh) 2023-06-06
US20200140420A1 (en) 2020-05-07
EP3191475B1 (en) 2020-07-29
ES2819242T3 (es) 2021-04-15
ZA201701320B (en) 2020-07-29
CA2958666A1 (en) 2016-03-17
LT3191475T (lt) 2020-10-12
CN105461702A (zh) 2016-04-06
WO2016037550A1 (en) 2016-03-17
JP2019065019A (ja) 2019-04-25
CL2017000540A1 (es) 2017-09-15
JP2017526710A (ja) 2017-09-14
KR20190018056A (ko) 2019-02-20
TW201609715A (zh) 2016-03-16
BR112017004000B1 (pt) 2023-10-24
CN111018846A (zh) 2020-04-17
SI3191475T1 (sl) 2021-02-26
IL250647B (en) 2020-11-30
NZ729884A (en) 2020-09-25
HRP20201501T1 (hr) 2020-12-25
US11046674B2 (en) 2021-06-29

Similar Documents

Publication Publication Date Title
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
BR112017004000A2 (pt) formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
BR112018073384A2 (pt) polinucleotídeos moduladores
IL248546B (en) A multi-fluorinated compound as an inhibitor of proton tyrosine kinase
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201691582A1 (ru) Новые фармацевтические препараты
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
EA201692219A1 (ru) Способы получения противовирусных соединений
ECSP17030878A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
BR112016015365A8 (pt) composto, composição farmacêutica e uso de um composto
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
DK3386991T3 (da) Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
BR112017028549A2 (pt) derivados de pirimidina como inibidores de btk e usos dos mesmos
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HUTCHMED LIMITED (CN)

B25G Requested change of headquarter approved

Owner name: HUTCHMED LIMITED (CN)

B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/09/2015, OBSERVADAS AS CONDICOES LEGAIS